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ABSTRACT Objectives: Obstructive sleep apnea (OSA) is frequently diagnosed in U.S. military personnel. OSA is
associated with sleepiness, poor sleep quality, and service-related illnesses of insomnia, depression, post-traumatic
stress disorder, and traumatic brain injury. Methods: Observational study of active duty military personnel with OSA
and adherence to positive airway pressure (PAP) assessed with smart chip technology. Results: 58 men with mean age
36.2 ± 7.7 years, mean body mass index 31.4 ± 3.7 with mean apnea–hypopnea index (AHI) 19.1 ± 19.0 are reported.
23 (39.7%) participants were adherent to PAP, and 35 (60.3%) were nonadherent. No significant differences in baseline
demographics, apnea–hypopnea index, service-related illnesses, or clinical instrument scores. Military personnel adherent
to PAP had significantly improved sleepiness ( p = 0.007), sleep quality ( p = 0.013), depressive symptoms ( p = 0.01),
energy/fatigue ( p = 0.027), and emotional well-being ( p = 0.024). Participants with moderate–severe OSA were
more likely to be in the adherent group when compared with participants diagnosed with mild OSA. Conclusions:
Military personnel with OSA have low adherence to PAP. Adherence is associated with improved depressive symp-
toms, sleepiness, sleep quality, energy/fatigue, emotional well-being, and social functioning. Future research should
focus on interventions to improve the management of OSA in military personnel.
INTRODUCTION
Sleep disturbances are the most frequently endorsed symp-
toms of military personnel who have deployed to Iraq and
Afghanistan. From 2000 to 2009, the diagnosis of obstruc-
tive sleep apnea (OSA) increased six fold.1 In more recent
studies, OSA is one of the most frequently reported clinical
diagnoses among returning service members with sleep dis-
turbances, with rates ranging from 34.5% to 76.8%.2–4 The
clinical characteristics of military personnel with OSA are
different from civilians. Specifically, they are sleepier by
self-reported scores on the Epworth Sleepiness Scale (ESS)
with an average score of 135,6 and tend to have more normal
body mass index (BMI).5,6 Sleepiness in military personnel
with OSA is likely multifactorial. In part, this symptom is a
consequence of their OSA, but insufficient sleep with an
average reported sleep duration of 6 hours7,8 and comorbid,
service-related illnesses, such as anxiety, depression, insom-
nia, post-traumatic stress disorder (PTSD), or traumatic brain
injury (TBI) likely contribute.2,3,6,7
Military personnel with OSA are primarily treated with
positive airway pressure (PAP) therapy.9 Similar to the
American College of Chest Physicians commercial vehicle
guidelines,10 there are regulations that allow military per-
sonnel with OSA, who are AD to PAP, to remain on
active duty and deploy to austere environments.11 How-
ever, military personnel have a rigorous profession, which
is physically and mentally demanding. They frequently
have mission requirements, which result in sleep deprivation
that could limit their adherence, as well as the effectiveness
of PAP.7,8 In addition to sleep deprivation, insomnia is
a common comorbid diagnosis in military personnel with
OSA. In civilians, comorbid insomnia and OSA is associ-
ated with decreased rates of PAP adherence.12
Adherence to PAP is suboptimal in civilian patients, but
even more so in military personnel.13–15 Reports of PAP
adherence in military personnel are limited and have focused
on PTSD. Collen et al15 reported adherence rates of 25.2% in
active duty soldiers with PTSD compared with 58.3% in
those without PTSD. Another study of veterans with OSA
reported adherence rates of 41% in those with PTSD and
70.0% in those without.16 These findings suggest that active
duty status may have a role in adherence. As untreated OSA
is associated with sleepiness, poor sleep quality, and increased
risks of mental lapses and motor vehicle accidents, PAP
adherence may have substantial implications on military
medical readiness.17–19
In civilians, PAP adherence has been associated with
improvements in objective findings and subjective reports.
Daytime sleepiness as measured by the ESS was significantly
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improved with adherence to PAP therapy.20–22 Likewise,
studies have demonstrated significant improvements on
quality of life measures using the Short Form Health Survey
(SF-36). PAP therapy has been shown to improve SF-36
measures of vitality and energy.23,24 In terms of objective
benefits associated with PAP adherence, there are several
studies that have suggested a link between PAP adherence and
neurocognitive performance and cardiovascular health.25–29
Despite the evidence that treatment with PAP improves
OSA and sleepiness in civilian patients,13,30 to our knowl-
edge, there are no studies that have established the effective-
ness of PAP therapy in an active duty military population. In
this study, we examined PAP adherence rates in active duty
military personnel and the effects of PAP adherence on
sleepiness, sleep quality, and health-related quality of life.
As OSA is associated with service-related illnesses, we also
evaluated if symptoms of depression and PTSD improved
with adherence to PAP therapy.
METHODS
Study Design
We conducted an observational study assessing 58 active duty
military personnel who underwent a sleep medicine evaluation
within 18 months of their most recent deployment and were
diagnosed with OSA (Fig. 1). From the time of enrollment, par-
ticipants were followed for a period of 90 days per the study
protocol. The baseline clinical assessments were performed at
enrollment. The polysomnogram (PSG) was conducted within
4 weeks and participants were seen for follow-up within 2 weeks
of the study. The participants were followed in the Sleep Medi-
cine Clinic for PAP therapy adherence and usual clinical care.
All clinical appointments were modified as required by the
participant’s military duties. This study was a follow-on of
our initial larger cohort that assessed sleep diagnoses in
military personnel recently returned from deployment.6
Participants diagnosed with OSA were treated in accor-
dance with our clinical algorithm. This included counseling
and education regarding their diagnosis and discussion of
treatment options. Potential clinical efficacy of PAP therapy,
a dental orthotic, and surgery are discussed. If a patient elects
PAP therapy, it is our standard practice to use autotitrating
PAP (APAP) for patients with OSA. Those choosing APAP
received routine clinical follow-up, including a PAP therapy
data download with an outpatient respiratory therapist
4 to 6 weeks after APAP initiation. If alternate treatment was
desired for OSA, the patient was then excluded from the
analysis. As this was an observational study, no other
FIGURE 1. Consort table.
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interventions besides our usual clinical care were performed.
The study was approved by the Institutional Review Board
at Madigan Army Medical Center in Tacoma, Washington.
Participants
Participants were a convenience sample of 58 male military
personnel who were recruited on presentation to the Sleep
Medicine Clinic for evaluation of sleep disturbances. For
the current analyses, military personnel were between 20 and
53 years old. Participants were primarily European Americans
(65.5% European Americans, 13.8% African-Americans,
6.90% Hispanic/Latino, 1.72% Native Alaskan, 1.72% Pacific
Islander, and 10.3% mixed ethnicity), with education rang-
ing from 10 to 20 years (mean = 13.8, standard deviation
[SD] = 1.84). The majority were active duty U.S. Army
(91.4% Army, 8.62% Air Force), Junior Enlisted (58.6%
E1 to E4, 37.9% E5 to E9, and 3.45% Officers), and had
deployed from 1 to 20 times (median = 2). For 17.2% of the
participants, their last deployment was less than 3 months
before enrollment in the study, 3 to 6 months for 12.1%, 6 to
12 months for 34.5%, and 12 to 18 months for 36.2%. The
most frequently observed service-related illness was insomnia
(63.8%), followed by depression (51.7%), mild traumatic brain
injury (mTBI) (41.4%), pain (39.7%), and PTSD (25.9%).
Measures
Biometric parameters of age, ethnicity, education, branch of
service, rank, number of deployments, time since last deploy-
ment, BMI, and service-related illnesses of insomnia, PTSD,
depression, and mTBI) were obtained.
APAP Adherence
All patients were offered a trial of APAP with adherence
assessed 4 to 6 weeks after initiation of treatment. The most
recent 30-day period of use was assessed to determine if
the participant was AD. Participants were placed in the
AD group if they used APAP more than 4 hours a night for
70% or more of nights during a consecutive 30-day period.31
Participants who did not meet these criteria were placed in
the nonadherent (NAD) group.
PTSD Checklist—Military Version (PCLM)
The PCLM was used to assess symptoms of PTSD, with a
cutoff score of 50 indicating a positive diagnosis of PTSD
and provides the maximum specificity (0.98).32,33
Quick Inventory of Depressive Symptomatology (QIDS)
The diagnosis of depression, as well as changes in symptoms,
was assessed through the QIDS.34 A score of 11, which is
indicative of moderate–severe depression, resulted in a posi-
tive screen for this disorder.
RAND 36-Item Short Form Health Survey (SF-36)
The SF-36 was used to assess the health-related quality
of life in study participants.35 The SF-36 consists of eight
health concepts: physical functioning, bodily pain, role
limitations because of physical health problems, role limi-
tations because of personal or emotional problems, emo-
tional well-being, social functioning, energy/fatigue, and
general health perceptions.
Pain and mTBI
The bodily pain component of the SF-36 as well as the
patients’ electronic medical record was used in determining
pain diagnosis. A positive screen was rendered by either a
score of <70% and a diagnosis in electronic medical record or
a low bodily pain score <30% on the SF-36.36 In accordance
with the American Congress of Rehabilitation Medicine
criteria,37 mTBI was diagnosed when an injury was followed
by loss of consciousness or alteration of mental state as
reported on the Warrior Administered Retrospective Casualty
Assessment Tool.38
PSG Evaluation
All participants underwent a diagnostic attended PSG using
standardized techniques we have previously reported.6 The
PSG variables we analyzed included sleep onset latency,
rapid eye movement onset latency, total sleep time, wake-
fulness after sleep onset, sleep efficiency, arousal index,
sleep stages (stage N1, stage N2, stage N3, stage R), apnea–
hypopnea index (AHI), and maximal desaturation. Sleep
diagnoses were rendered in accordance with the International
Classification of Sleep Disorders.39
Epworth Sleepiness Scale
The ESS assessed patients’ sleepiness.40 The participants
rated from 0 (would never doze) to 3 (high chance of dozing)
how likely they are to fall asleep in eight situations. The total
ESS score, ranges from 0 (better) to 24 (worse). A score
>10 indicates abnormal sleepiness.
Pittsburgh Sleep Quality Index (PSQI)
The PSQI was used to determine sleep quality during the
previous month.41 The PSQI includes 18 questions that yield
seven component scores (sleep quality, sleep latency, dura-
tion, sleep efficiency, sleep disturbances, sleep medica-
tion use, and daytime dysfunction) rated from 0 (better)
to 3 (worse). The total score, ranging from 0 (better) to
21 (worse), is the summation of the component scores.
Individuals with a PSQI total score £5 are characterized
as good sleepers, whereas scores >5 are associated with
poor sleep quality. The PSQI has a sensitivity of 89.6%
and a specificity of 86.5% (k = 0.75, p < 0.001), and an
internal consistency a = 0.83.41
Statistical Analysis
Statistical analysis was conducted with a statistical software
package (JMP Pro 9; SAS Institute, Cary, North Carolina).
All variables underwent descriptive statistical analysis to
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describe our population in terms of demographic charac-
teristics of military personnel. Based on the criteria already
described, participants were classified in the AD and NAD
groups. First, we assessed the statistical equivalence between
the two groups. Then, we performed a nonparametric com-
parison, based on Wilcoxon rank-sum test, between the
AD and NAD groups. The intent was to identify whether
the two patient groups differed in demographics (age, BMI),
PSG parameters, PCLM, QIDS, SF-36, ESS, PSQI, service-
related illnesses (PTSD, depression, mTBI, pain, and insom-
nia), and OSA.
RESULTS
Participants were a relatively young, at 36 years of age
(20–53 years), cohort of males with an average BMI of
31.4 (SD = 3.7) (Table I). 23 participants (39.7%) were
AD with APAP and included in the AD group, whereas
35 (60.3%) NAD participants were included in the NAD
group (Fig. 1). There were no significant differences in
baseline values between the participants in the AD and the
NAD groups in demographics, PSG parameters, PCL-M,
QIDS, SF-36, ESS, and PSQI scores (Wilcoxon rank-sum
test, p > 0.05). The arousal index did approach significance
( p = 0.103), elevated in the AD group, likely corresponding
to their AHI values. No significant differences were iden-
tified in the presence of service-related illnesses (PTSD,
depression, mTBI, pain, and insomnia) between the two
groups (likelihood ratio test, p > 0.30).
Not surprisingly, there were significant differences between
the AD and NAD groups in APAP usage (Table II). The AD
group used APAP on virtually all nights of the download
(mean = 29.9 nights, SD = 8.46) compared to the NAD group,
which used APAP on average 10.1 (SD = 10.9) nights of the
download (Wilcoxon rank-sum test, c2(1) = 25.3, p < 0.001).
The AD group had a mean nightly usage of 5.46 (SD = .84)
hours, whereas the NAD group averaged 2.71 (SD = 1.74)






(n = 35) p-Valuea
Demographicsb
Age, Years 36.2 ± 7.73 37.7 ± 7.96 35.2 ± 7.53 0.252
BMI, kg/m2 31.4 ± 3.69 31.8 ± 4.28 31.1 ± 3.29 0.639
Service-Related Illnesses
PTSD, % (n) 25.9 (15) 26.1 (6) 25.7 (9) 0.975c
Depression, % (n) 51.7 (30) 56.5 (13) 48.6 (17) 0.553c
Pain, % (n) 39.7 (23) 47.8 (11) 34.3 (12) 0.303c
Mild TBI, % (n) 41.4 (24) 47.8 (11) 37.1 (13) 0.420c
Insomnia, % (n) 63.8 (37) 60.9 (14) 65.7 (23) 0.707c
PSG Variablesb
SOL, Minutes 9.3 ± 11.8 8.9 ± 8.7 9.5 ± 13.7 0.399
REM Latency, Minutes 105 ± 74.8 108 ± 72.4 100 ± 75.3 0.668
TST, Minutes 418 ± 64.9 406 ± 73.5 425 ± 59.6 0.206
Sleep Efficiency, % 90.7 ± 6.1 88.7 ± 7.0 91.3 ± 5.5 0.117
Stage N1, % 13.2 ± 8.4 14.3 ± 11.5 12.6 ± 5.8 0.980
Stage N2, % 42.9 ± 10.1 41.5 ± 11.4 43.6 ± 9.4 0.883
Stage N3, % 18.6 ± 9.8 18.0 ± 12.3 18.7 ± 8.1 0.193
Stage R, % 18.9 ± 9.7 20.4 ± 14.2 18.1 ± 5.3 0.943
WASO, Minutes 40.9 ± 26.4 45.4 ± 33.5 39.7 ± 20.2 0.893
Arousal Index 25.3 ± 19.1 31.1 ± 25.4 21.8 ± 13.3 0.103
AHI 19.1 ± 19.0 24.1 ± 25.7 15.8 ± 12.7 0.206
Desaturation, % 83.8 ± 6.2 82.7 ± 6.8 84.5 ± 6.0 0.398
BMI, body mass index in kilogram per square meter; SOL, sleep onset latency; REM, rapid eye movement; TST, total sleep time; WASO, wakefulness
after sleep onset; AHI, apnea hypopnea index. aNonparametric Wilcoxon rank-sum test for differences between AD and NAD groups. bData are presented
as mean ± SD. cLikelihood ratio test. *p < 0.05; **p < 0.01; ***p < 0.001.






(n = 35) p-Valueb
Number of Days Assessed 30.2 ± 7.27 31.1 ± 8.70 28.5 ± 3.57 0.236
Number of Days Used 24.8 ± 10.9 29.9 ± 8.46 16.3 ± 9.37 <0.001***
Mean Nightly Use, Hours 4.39 ± 1.84 5.46 ± 0.84 2.71 ± 1.74 <0.001***
Residual AHI 2.12 ± 2.61 2.02 ± 1.76 2.32 ± 3.85 0.330
aData are presented as mean ± SD. bNonparametric Wilcoxon rank-sum test for differences between AD and NAD groups. *p < 0.05; **p < 0.01;
***p < 0.001.
MILITARY MEDICINE, Vol. 180, April 2015478
Adherence to PAP Therapy in U.S. Military Personnel
Downloaded from publications.amsus.org: AMSUS - Association of Military Surgeons of the U.S. IP: 152.131.008.131 on Apr 14, 2015.
Copyright (c) Association of Military Surgeons of the U.S. All rights reserved.
hours a night (Wilcoxon rank-sum test, c2(1) = 22.8, p <
0.001). 32 patients (55.2%) were diagnosed with mild OSA,
whereas 18 (31.0%) had moderate and 8 (13.8%) had severe
OSA. Those diagnosed with moderate to severe OSA were
more likely to be in the AD group when compared with par-
ticipants diagnosed with mild OSA (likelihood ratio test,
c2(1) = 3.99, p = 0.046), see Figure 2.
Next, we investigated how clinical symptoms changed
from the baseline to the follow-up assessment by calculating
the difference scores (follow-up score − baseline score). This
analysis showed that APAP adherence affected QIDS, ESS,
PSQI, and the energy/fatigue and emotional well-being
indices of SF-36. Specifically, there was a 2.61 decrease
in the QIDS scores of the AD group from baseline to
follow-up, which was significantly different compared to the
NAD group (D = 0.09, Wilcoxon rank-sum test, p = 0.01).
Sleepiness, as assessed by the ESS, was reduced in the AD
group by an average of 4.88 points, which was significantly
decreased compared to the 0.67 points decrease in NAD
group ( p = 0.007). The AD group also decreased the PSQI
scores by an average of 5.18 points as compared to the
1.17 points decrease in the NAD group ( p = 0.001). Mili-
tary personnel in the AD were significantly more likely to
have a normal PSQI score (PSQI £ 5: AD = 41.2%; NAD =
6.7%; likelihood ratio test: c2(1) = 8.18, p = 0.004). Differ-
ences in ESS scores between AD and NAD groups were
evident but not statistically significant (ESS £ 10: AD =
39.8%; NAD = 28.6%; likelihood ratio test: c2(1) = 0.697,
p = 0.404). These results are depicted on Figure 3.
Furthermore, APAP adherence affected three quality of
life factors on the SF-36. In the AD group, energy/fatigue
score increased by 12 points and emotional well-being increased
by 8 points, whereas energy/fatigue decreased by 1 point and
emotional well-being increased by 1.1 in the NAD group
(Wilcoxon rank-sum test, p < 0.05). Social functioning showed
a trend toward significance between the two groups, with
the AD group having an average increase of 4.8 points and
the NAD group showing an average decrease of 4 points
(Wilcoxon rank-sum test, p = 0.087).
These results show that adherence with the APAP use was
associated with decreased sleepiness, improved sleep quality,
energy/fatigue, emotional well-being, and social functioning.
The symptoms’ scores in the AD and NAD groups are shown
in detail in Table III.
DISCUSSION
The results of this study indicate a significant association
between APAP adherence and improvements of subjective
sleepiness, social functioning, and sleep quality in military
participants. To our knowledge, this is the first study of
PAP adherence to demonstrate these improvements in active
duty military personnel. It is not necessarily surprising to
see improvements in fatigue, sleepiness, and sleep quality in
patients who are APAP AD; however, these improvements
occurred in military personnel with substantial comorbid
illnesses and short sleep duration. There were also signifi-
cant improvements in depression by the QIDS, which is
consistent with previous literature showing depressive symp-
tom improvements with continuous positive airway pressure
(CPAP) treatment.42,43
Our results are consistent with civilian studies, which have
shown improvements in subjective sleepiness, sleep quality,
and quality of life associated with PAP adherence. Previous
studies have shown a 4- to 7-point improvement in ESS
scores depending on CPAP adherence.20 These findings cor-
relate with an improvement of greater than 5 points in the
ESS and PSQI with our study sample. Likewise, this study
confirms previous findings linking PAP adherence with sig-
nificant improvements in quality of life as measured by the
SF-36.23 AD participants also reported improvements in their
energy and emotional well-being. Yet, when looking at the
ESS and PSQI, only 39.1% and 41.2% of AD participants had
normalized values. This finding suggests that insufficient
sleep and comorbid service-related illnesses may contribute
to sleepiness and poor sleep quality in military personnel.
Overall, 71% of participants in our study had a comor-
bid service-related illness. Although the findings show an
improvement in depression, they failed to show a significant
improvement in PTSD-related symptoms or pain as indicated
FIGURE 3. Military personnel with normal ESS and PSQI by APAP
adherence. Percent of military personnel with normal ESS and PSQI at
follow-up for participants who were AD versus NAD with APAP.
FIGURE 2. OSA severity by CPAP adherence.
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in the PCL-M and SF-36 scores, respectively. Previous studies
of nonactive duty patients with PTSD have shown signifi-
cant improvements in nightmares and symptom presentation
with CPAP adherence.16,44 Approximately one-quarter of the
AD (6) and NAD (9) groups were diagnosed with PTSD. With
the small number of participants with PTSD and the complex
nature of this disease, our study was likely not adequately
powered to detect a difference in PTSD symptoms in a subset
of the study population with a short duration of APAP therapy.
The majority of participants, 66.1%, were obese with a
BMI ³ 30. The prevalence of obesity in the military is
12.9%,45 which is lower than the prevalence of 32.9% and
35.5% in men and women of the general U.S. population.46
This comorbid medical disorder, which likely contributed
to their OSA diagnosis, should also be part of the treatment
plan for patients with OSA.
APAP adherence has been reported to reduce depressive
symptoms at both short-term and long-term follow-up.47
Conversely, nonadherence is associated with depression and
anxiety.48 Means et al42 reported significant improvements in
depression scores, utilizing the Beck Depression Inventory,
in patients treated with CPAP, as well as continued improve-
ments of both somatic and affective/cognitive symptoms
on the Beck Depression Inventory after 3 months of CPAP
treatment. The majority of participants in our study at base-
line (51.7%) had symptoms consistent with major depressive
disorder with a QIDS score > 11. This finding is consistent
with several previous studies documenting the association
between OSA and depression.49–51 Overall, depressive symp-
toms, as indicated by the QIDS, significantly improved with
APAP adherence. Some have suggested that restoration
of sleep architecture, resolution of nocturnal hypoxia, and
improved daytime symptoms of sleepiness and fatigue may
contribute to the resolution of depressive symptoms.52 This
finding, as corroborated by the previously cited work, under-
scores the importance of integrating behavioral health sur-
veillance for and treatment of OSA, as appropriate treat-
ment can improve depressive symptoms, whereas untreated
depression and PTSD may present a significant barrier to PAP
therapy adherence.53
Among military personnel and veterans, the prevalence
of OSA is relatively high but adherence to PAP therapy is
low. The PAP adherence rate we report, 39.7%, is similar
to the studies by Collen et al15 (25.2%) and El Solh et al16
(40%) in soldiers and veterans with PTSD. However, unlike
Collen et al, we did not find that the presence of service-related
illnesses (PTSD, depression, mTBI, pain, and insomnia) were
associated with APAP adherence. This difference could be
potentially explained by the low PTSD severity within our
sample with a mean PCL-M of 41.3 in our AD group and the
participants’ proximity to returning from combat within the
last 18 months. Likewise, the generally high rate of insuffi-
cient sleep in military personnel, which is in part because
of their military duties, likely contributes to the relatively
short usage of 5.46 hours in our AD group.
Military personnel with moderate to severe OSA in our
study had improved APAP adherence. These data are consis-
tent with previous studies demonstrating weak associations
between OSA severity and APAP adherence.54 The implica-
tion of these findings though, remains unclear given our
small sample size and the high rate of comorbid diseases,
which are known to impact APAP adherence. AD partici-
pants with more severe disease are more likely to experi-
ence recognizable improvements compared to those with
mild OSA. The self-realization of these gains may reinforce
their adherence.
There are some limitations to address in this study. This
was an observational study with a small sample size, which
may limit the generalizability of the results. Given the small
size, this study was likely underpowered to demonstrate
significant relationships between comorbid service-related
illnesses and PAP adherence. However, our findings are
TABLE III. Improvement of Symptoms in AD versus NAD Military Personnel
All(N = 58) CPAP AD(n = 23) CPAP NAD(n = 35) Change Score
Baseline Baseline Follow-Up Baseline Follow-Up p-Valuea
Clinical Instruments
PCL-M 40.5 ± 16.9 41.3 ± 15.5 39.1 ± 17.5 40.0 ± 18.0 40.9 ± 18.0 0.206
QIDS 10.8 ± 5.03 10.8 ± 4.06 8.22 ± 5.09 10.8 ± 5.63 10.7 ± 6.0 0.010**
SF-36
Bodily Pain 57.1 ± 25.6 57.7 ± 25.2 57.2 ± 23.6 56.6 ± 26.2 53.4 ± 26.6 0.894
Physical Functioning 75.1 ± 20.3 75.4 ± 19.4 73.7 ± 23.7 75.0 ± 21.1 70.4 ± 24.7 0.200
Physical Role Limitations 49.7 ± 44.2 54.4 ± 44.4 51.1 ± 37.3 46.6 ± 44.5 44.9 ± 43.9 0.938
Emotional Role Limitations 60.9 ± 43.8 59.4 ± 46.0 63.7 ± 42.6 61.9 ± 42.9 56.9 ± 43.9 0.430
Energy, Fatigue 33.0 ± 20.0 31.5 ± 20.6 43.5 ± 24.4 34.0 ± 19.9 32.7 ± 19.3 0.027*
Emotional Well-Being 58.3 ± 22.6 57.4 ± 21.2 65.4 ± 21.8 59.0 ± 23.7 60.6 ± 22.6 0.024*
Social Functioning 64.0 ± 27.4 61.7 ± 28.1 66.5 ± 28.3 65.5 ± 27.2 61.2 ± 29.0 0.087
General Health 56.0 ± 21.4 56.1 ± 18.8 55.9 ± 22.7 56.0 ± 23.3 53.1 ± 22.6 0.225
ESSb 13.9 ± 5.28 12.8 ± 4.76c 7.65 ± 4.81c 14.6 ± 5.55 14.0 ± 5.17 0.007**
PSQIb 13.0 ± 3.95 12.8 ± 4.20c 7.65 ± 4.53c 13.2 ± 3.87 11.8 ± 3.45 0.013*
aNonparametric Wilcoxon rank-sum test for differences between AD and NAD groups. bESS and PSQI evaluated in 48 participants. cData are presented as
mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
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consistent with previous civilian studies, which further
emphasize their importance. Accommodating the military
duties and requirements, this initial study of PAP adher-
ence demonstrated improvements in subjective sleepiness,
social functioning, and sleep quality in active duty military
personnel. Although definite conclusions cannot be made,
follow-up studies should further assess and verify our find-
ings with larger active duty military populations. We used
a standardized definition of adherence and did not account
for restricted sleep periods due to military requirements.
It is possible that the 50% of the NAD group that used
APAP were deemed NAD due to this factor. Since this
was an observational study on active duty patients receiv-
ing treatment for OSA, randomization to a placebo arm
receiving sham CPAP was not possible. As sham CPAP
has been shown to improve quality of life,55 it is possible
that some of the improvements in the AD group were not
exclusively because of positive pressure therapy. Multi-
ple providers prescribed treatment according to our usual
clinical algorithm, but not a study algorithm, this could
have resulted in variations in practice that not only influ-
enced treatment choices but also adherence to PAP. In
addition, patients may have received treatment for other
service-related illnesses concurrently which may have con-
tributed to their improved sleep. Importantly though, we
demonstrated that within 90 days of clinical evaluation
of Soldiers and Airmen with restricted sleep periods and
multiple comorbid illnesses, PAP adherence improved their
sleep and depressive symptoms.
Sleep disturbances are the signature illness of military
service, affecting nearly all active duty military personnel.
Military personnel with comorbid service-related illnesses
typically have more disturbed sleep and thus are more likely
to require a formal sleep medicine evaluation. Diagnosing
and treating OSA can improve depressive symptoms, sleepi-
ness, sleep quality, energy/fatigue, emotional well-being, and
social functioning.42,43 Although the military has begun to
recognize the importance of sleep, there is little objective data
establishing effective treatment regimens and outcomes for
this high-risk population. Future research is required to estab-
lish OSA treatment protocols for military personnel and
veterans and develop multidisciplinary treatment models,
which integrate their comorbid service-related illnesses.
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